Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer

Giandomenico Roviello, Monica Ramello, Martina Catalano, Alberto D'Angelo, Raffaele Conca, Silvia Gasperoni, Lorenzo Dreoni, Roberto Petrioli, Anna Ianza, Stefania Nobili, Michele Aieta, Enrico Mini

Research output: Contribution to journalArticle

Abstract

Neutropenia is a common side effect associated with nab-paclitaxel gemcitabine (Nab-Gem) therapy. We retrospectively investigated the association between neutropenia induced by first-line Nab-Gem and survival in metastatic pancreatic carcinoma patients. Metastatic pancreatic patients treated with first-line Nab-Gem were included in this retrospective analysis. Neutropenia was categorized using the National Cancer Institute Common Toxicity Criteria scale. Outcome measures were overall survival (OS), progression-free survival (PFS) and response rate. 115 patients were analyzed. Median PFS was 7 months (95% CI 5-8) for patients with grade ≥ 3 neutropenia and 6 months (95% CI 5-6) for patients with grade < 3 neutropenia [p = 0.08; hazard ratio (HR 0.68)]. Median OS was 13 months (95% CI 10-18) for patients with grade ≥ 3 neutropenia and 10 months (95% CI 8-13) for patients with grade < 3 neutropenia (p = 0.04; HR 0.44). In multivariate analysis, the occurrence of grade ≥ 3 neutropenia showed a statistically significant association with OS (HR 0.62; 95% CI 0.09-0.86; p = 0.05). Nab-Gem-induced neutropenia is associated with longer survival in metastatic pancreatic cancer patients.

Original languageEnglish
Article number19281
JournalScientific Reports
Volume10
Issue number1
DOIs
Publication statusPublished - 6 Nov 2020

Fingerprint Dive into the research topics of 'Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer'. Together they form a unique fingerprint.

Cite this